Once-daily therapy: Less is more
Author:
- 1 October 2003
- journal article
- review article
- Published by SAGE Publications in International Journal of STD & AIDS
- Vol. 14 (1_suppl) , 1-5
Abstract
Over the last 20 years, a trend towards regimens with less frequent dosing has been observed across medicine. Recent surveys of people with HIV indicate that there is a strong preference for once-daily dosing and compact therapy. Four antiretrovirals (tenofovir, didanosine, lamivudine and efavirenz) are now available as once-a-day therapies. The range of once-daily options is expanding rapidly, with the potential for two lines of once-daily therapy to be available in the next 12–18 months.Keywords
This publication has 5 references indexed in Scilit:
- Results of a Phase 2 Clinical Trial at 48 Weeks (AI424-007): A Dose-Ranging, Safety, and Efficacy Comparative Trial of Atazanavir at Three Doses in Combination with Didanosine and Stavudine in Antiretroviral-Naive SubjectsJAIDS Journal of Acquired Immune Deficiency Syndromes, 2003
- Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNAAIDS, 2001
- A systematic review of the associations between dose regimens and medication complianceClinical Therapeutics, 2001
- Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adultsAIDS, 2001
- Adherence to Protease Inhibitor Therapy and Outcomes in Patients with HIV InfectionAnnals of Internal Medicine, 2000